Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Company's industry-first technology addresses chronic low back painAclarion secured its first commercial agreement with Mic...
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and lowers the price target from $1.6 to $...
Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After R...
Sheridan Community Hospital is the First Healthcare Institution in Michigan With NociscanAgreement Expands Nociscan Access to J...
Ascendiant Capital analyst Lucas Ward initiates coverage on Aclarion (NASDAQ:ACON) with a Buy rating and announces Price Tar...
https://register.epo.org/application?number=EP21157092
